Aiming to be a company with sustained growth, Nissui Pharmaceutical views FY2019 to FY2020—the period covered by its medium-term management plan—as a stage for increasing investment in the creation of new value.
* In FY2021, we continue the medium-term management plan for FY2019-2020.
Position of the Medium-Term Management Plan (FY2019-2020)
FY2019–2020 is a period for vigorous investment in the creation of new services. Steps taken to date are beginning to produce earnings, and sustained earnings growth is expected.
Nippon Suisan Kaisha, Ltd. and Nippon Suisan Group companies are strengthening their investment management, with ROA as a performance indicator.
Initiatives for Profitable Growth
Perform more device installments in major hospitals and clinical laboratory centers in Japan
Expand the control serum business
Strengthen the infectious disease product line
Expand sales of regenerative medicine products
Add HACCP- and ISO-related products and services
Extend the pharmaceutical- and food-testing product line
Operational improvement: Automation, consolidation, and outsourcing
Optimal human resource deployment: Creative work, work efficiency improvements, quality maintenance
Overseas Business Development
Continue to designate key sales regions, while adding new sales agents, to further expand global business development.
Regenerative Medicine Business (Mycoplasma testing)
Safety is a top priority for the quality of regenerative medicine products and biopharmaceuticals, and mycoplasma detection is a critical element of safety testing. In the global market for mycoplasma detection we aim to supply our Myco Finder mycoplasma negative test kits not only to customers in Japan but also to major pharmaceutical manufacturers engaged in antibody medicine and regenerative medicine research and product development in Europe and the U.S.
Source: "Latest Trends and Future Potentiality of Tissue Engineering Related Market 2018," a research report published by Fuji Keizai Co., Ltd.
SAS (Société par actions simplifiée)
Département d’Anesthésie Réanimation, Hôpital de la Pitié Salpêtrière, 47/83 boulevard de l’hôpital, 75013 Paris, France
Nissui Pharmaceutical Co., Ltd. 100%
Overseas business in regenerative medicine industry, Myco Finder® sales
Food Safety Management
About the ＠BactLAB colony counter global cloud service
＠BactLAB’s cloud-based data management function makes it possible for hygiene management conditions to be monitored not only by the quality control unit of a supplier or factory but also by a headquarters unit (QC/QA department). Real-time monitoring can be set up for every step from raw material production through the supply of products.
Investments in and Alliances with Other Companies and Research Institutions
Bioventure and research- and manufacturing-related companies
Contribution to the treatment of familial LCAT deficiency
Tokyo Medical and Dental University
Study of the treatment of antiviral immune cells
Study of culture technique generating artificial platelet from subcutaneous adipose tissue
Kola-Gen Pharma Inc.
Manufacture and sales of reagents for synthetic collagen research, and R&D on biomaterials for medical applications
Saliva Tech Co., LTD
Research on simplified saliva-based tests for the detection of cancers
Early-Stage (Basic, Pre-clinical) Discoveries Nissui Pharmaceutical’s NeyeS Open Innovation Program
This program aims to discover innovative, unique ideas and know-how using everything from basic academic research through clinical research/testing and information processing in the areas of regenerative medicine technology, cell culturing, and testing and detection technology.
To create a sustainable company
To achieve long-term growth
To generate new business in open innovation
To add value to existing products through online accessibility to provide services globally